IOVANCE BIOTHERAPEUTICS, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $263.5M | $164.1M | $1.2M | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | $173.2M | $93.2M | $1.0M | — | — | — | — | — |
| Gross Profit | $90.3M | $70.8M | $156.0K | — | — | — | — | — |
| Gross Margin | 34.3% | 43.2% | 13.1% | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $300.3M | $276.2M | $333.2M | $99.8M | $71.6M | $26.9M | $15.5M | $3.8M |
| SG&A Expense | $152.3M | $152.3M | $106.1M | $28.4M | $21.3M | $26.7M | $12.4M | $8.2M |
| Operating Income | $-403.4M | $-395.3M | $-460.6M | $-128.3M | $-92.9M | $-53.6M | $-27.9M | $-12.0M |
| Operating Margin | -153.1% | -240.9% | -38,735.0% | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | $-5.7K |
| Pretax Income | $-393.0M | $-375.0M | $-447.5M | — | — | — | — | — |
| Income Tax Expense | $-2.1M | $-2.8M | $-3.5M | $0 | $0 | $0 | $0 | $0 |
| Net Income | $-391.0M | $-372.2M | $-444.0M | $-123.6M | $-92.1M | $-52.9M | $-27.7M | $-12.0M |
| Net Margin | -148.4% | -226.8% | -37,345.4% | — | — | — | — | — |
| EPS (Basic) | $-1.09 | $-1.28 | $-1.89 | $-1.27 | $-1.41 | $-1.85 | $-0.62 | $-0.48 |
| EPS (Diluted) | $-1.09 | $-1.28 | $-1.89 | $-1.27 | $-1.41 | $-1.85 | $-0.62 | $-0.48 |
| Shares Outstanding (Basic) | 357.3K | 289.9K | 235.1K | 123.4M | 73.2M | 62.2M | 48.5M | 33.8M |
| Shares Outstanding (Diluted) | 357.3K | 289.9K | 235.1K | 123.4M | 73.2M | 62.2M | 48.5M | 33.8M |
| Dividends Per Share | — | — | — | — | — | — | — | — |